The overall goal of the City of Hope Lymphoma SPORE is to develop translational studies to improve the treatment of Hodgkin and non-Hodgkin lymphoma. This application, consisting of four translational research projects and four cores, will develop novel approaches that are derived from molecular and immunologic studies in lymphoma and T-cell and antibody-based therapies. An important theme of the translational studies in this grant is to develop effective therapeutics for lymphoma that will reduce toxicities associated with current treatment regimens for Hodgkin and non-Hodgkin Lymphoma which can be utilized for treatment of older patients. Project 1 will study the effectiveness of cellular immunotherapy for B cell lymphoma utilizing engineered central memory derived CD19-specific T-cells. Investigators in this project have developed a T-cell genetic modification platform for expressing chimeric immunoreceptors that redirect antigen specificity and effector function of central memory T-cells towards cell surface epitopes on B cell lymphomas and will test the persistence and expansion of these cells after infusion. Because epidemiologic Studies indicate that stem cell damage from pretransplant therapeutic exposures may play a role in the subsequent development of myelodysplasia, Project 2 will longitudinally study a population of patients with Hodgkin and non-Hodgkin Lymphoma. The investigators will continue their studies of the cellular and molecular factors that are predictive for development of myelodysplasia, and to determine the molecular sequence of events that lead to this complication of treatment. In Project 3 investigators will test a molecularly engineered novel anti-CD20 IL-2 immunocytokine for the treatment of patients with 0020""""""""^ lymphoma. An important component of this project will be to delineate the immunologic effector mechanisms operative in immunocytokine-mediated anti-lymphoma in vivo activity. Project 4 will develop siRNA based therapeutics against transcription factors (STATS) important in lymphoma behavior using an antibody directed cyclodextrin nanoparticle for treatment of patients with B cell lymphoma. The projects in this Lymphoma SPORE will be supported by four cores including: Administration, Biostatistics and Research Informatics, Tissue Bank for Molecular and Cellular Studies, and Biological Manufacturing. This Lymphoma SPORE will also support a Developmental Research Program and a Career Development Program to foster the advancement of pilot translational research projects and young investigators focused on lymphoma.

Public Health Relevance

The overall goal of the Beckman Research Institute at City of Hope Lymphoma SPORE is to develop translational studies to improve the treatment of Hodgkin and non-Hodgkin Lymphoma. This application, consisting of four translational research projects and four cores, will develop novel approaches that are derived from molecular and immunologic studies of T-cell and antibody-based therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA107399-09
Application #
8731628
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Nothwehr, Steven F
Project Start
2004-09-02
Project End
2016-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
9
Fiscal Year
2014
Total Cost
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Budde, Lihua E; Wu, David; Martin, Daniel B et al. (2018) Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 183:601-607
Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730
Zhao, Xingli; Zhang, Zhuoran; Moreira, Dayson et al. (2018) B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Mol Ther 26:695-707
Adamus, Tomasz; Kortylewski, Marcin (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56-60
Herrera, Alex F; Moskowitz, Alison J; Bartlett, Nancy L et al. (2018) Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 131:1183-1194
Chen, Robert W; Palmer, Joycelynne M; Tomassetti, Sarah et al. (2018) Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol 11:87
Wang, Xiuli; Walter, Miriam; Urak, Ryan et al. (2018) Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Clin Cancer Res 24:106-119
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Mei, Matthew G; Cao, Thai M; Chen, Lu et al. (2017) Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biol Blood Marrow Transplant 23:1861-1869
Herrera, Alex F; Mei, Matthew; Low, Lawrence et al. (2017) Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 35:24-31

Showing the most recent 10 out of 97 publications